title: Quince peel polyphenolic extract blocks human colon adenocarcinoma LS174 cell growth and potentiates 5-fluorouracil efficacy.
abstract: BACKGROUND
  Development of alternative cancer-specific drugs would be of paramount importance to overcome toxicity toward normal tissues and tumor resistance. Here, we investigated the potential anti-tumoral effect of peel (Peph) and pulp polyphenolic extracts from the Tunisian quince Cydonia oblonga Miller on both no-tumorigenic cells NIH 3T3 Fibroblasts and HEK 293 cells and human colon adenocarcinoma LS174 cells.
  
  
  METHODS
  Cell proliferation and cytotoxicity were measured with MTT and LDH assays respectively. Cell cycle distribution and the apoptosis levels were assessed by flow cytometry. Intracellular reactive oxygen species (ROS) levels were determined using the fluorescent probe CM-H2DCFDA. Western blot was used to further characterize cell death and analyze the signaling pathways affected by Peph treatment. The expression level of VEGF-A was evaluated by real time quantitative PCR and further verified by quantifying the secreted cytokines by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  We found that Peph extract displayed the highest anti-proliferative effect specifically on LS174 cells. However, each Peph phenolic compound alone did not exhibit any anti-proliferative activity, suggesting a synergistic effect of phenolic molecules. Such effect was associated with a cell cycle arrest in the G1/S phase, a caspase-independent apoptosis and an increase of the ROS production. Peph extract inhibited the pro-survival signaling pathway NFκB and suppressed the expression of various cellular markers known to be involved in cell cycling (cyclin D1) and angiogenesis (Vascular Endothelial Growth Factor, VEGF). Interestingly, the combination Peph extract and 5-FU exerted synergistic inhibitory effect on cell viability.
  
  
  CONCLUSIONS
  These data propose the quince Peph extract as a promising cost effective non toxic drug to employ alone or in combination with conventional anti-colorectal cancer. Moreover, quince rich regimen may prevent the development and the progress of colon cancer.
authors.affiliation: Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale Appliquée Aux Maladies Infectieuses (LR11IPT04), Institut Pasteur de Tunis, 13 Place Pasteur, BP 74, 1002 Tunis-Belvédère, Tunisia ; Université de Tunis El Manar, 1068 Tunis, Tunisia.
authors.forename: Ichrak
authors.initials: I
authors.lastname: Riahi-Chebbi
authors.affiliation: Laboratoire de Recherche sur la Transmission, le Contrôle et l'Immunobiologie des Infections (LR11IPT02), Institut Pasteur de Tunis, 1002 Tunis, Tunisia ; Université de Tunis El Manar, 1068 Tunis, Tunisia.
authors.forename: Meriam
authors.initials: M
authors.lastname: Haoues
authors.affiliation: Laboratoire de Recherche sur la Transmission, le Contrôle et l'Immunobiologie des Infections (LR11IPT02), Institut Pasteur de Tunis, 1002 Tunis, Tunisia ; Université de Tunis El Manar, 1068 Tunis, Tunisia.
authors.forename: Makram
authors.initials: M
authors.lastname: Essafi
authors.affiliation: Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale Appliquée Aux Maladies Infectieuses (LR11IPT04), Institut Pasteur de Tunis, 13 Place Pasteur, BP 74, 1002 Tunis-Belvédère, Tunisia ; Université de Tunis El Manar, 1068 Tunis, Tunisia.
authors.forename: Ons
authors.initials: O
authors.lastname: Zakraoui
authors.affiliation: Institut National des Sciences Appliquées et de Technologie (INSAT), Université de Carthage, Tunis, Tunisia.
authors.forename: Sami
authors.initials: S
authors.lastname: Fattouch
authors.affiliation: Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale Appliquée Aux Maladies Infectieuses (LR11IPT04), Institut Pasteur de Tunis, 13 Place Pasteur, BP 74, 1002 Tunis-Belvédère, Tunisia ; Université de Tunis El Manar, 1068 Tunis, Tunisia.
authors.forename: Habib
authors.initials: H
authors.lastname: Karoui
authors.affiliation: Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale Appliquée Aux Maladies Infectieuses (LR11IPT04), Institut Pasteur de Tunis, 13 Place Pasteur, BP 74, 1002 Tunis-Belvédère, Tunisia ; Université de Tunis El Manar, 1068 Tunis, Tunisia.
authors.forename: Khadija
authors.initials: K
authors.lastname: Essafi-Benkhadir
keywords: 5-Fluorouracil; Anti-tumoral effect; Colon cancer; Cydonia oblonga Miller; Mechanism of action; Quince peel polyphenolic extract
references.citation: J Agric Food Chem. 2007 Feb 7;55(3):963-9
references.pmid: 17263500
references.citation: In Vivo. 2012 Nov-Dec;26(6):971-8
references.pmid: 23160680
references.citation: PLoS One. 2012;7(5):e36418
references.pmid: 22574158
references.citation: BMC Cancer. 2015 Mar 21;15:156
references.pmid: 25884995
references.citation: Arch Med Res. 2013 Jul;44(5):346-51
references.pmid: 23867787
references.citation: J Gastrointest Oncol. 2013 Dec;4(4):409-23
references.pmid: 24294513
references.citation: J Gastrointest Oncol. 2015 Apr;6(2):185-200
references.pmid: 25830038
references.citation: Front Pharmacol. 2013 Jan 31;4:5
references.pmid: 23386830
references.citation: Eur J Pharmacol. 2010 Jan 25;626(2-3):139-45
references.pmid: 19782062
references.citation: PLoS One. 2013 May 27;8(5):e64378
references.pmid: 23724044
references.citation: Food Chem Toxicol. 2009 Jun;47(6):1372-7
references.pmid: 19306906
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Dig Dis Sci. 2015 Aug;60(8):2251-63
references.pmid: 25840920
references.citation: J Agric Food Chem. 2010 Mar 24;58(6):3366-70
references.pmid: 20192210
references.citation: Cancer Biol Ther. 2011 Jul 1;12(1):59-68
references.pmid: 21532339
references.citation: IUBMB Life. 2011 Apr;63(4):221-32
references.pmid: 21438113
references.citation: PLoS One. 2012;7(6):e40152
references.pmid: 22761954
references.citation: Biochem Med (Zagreb). 2011;21(3):264-75
references.pmid: 22420240
references.citation: Mol Cancer. 2012 May 14;11:35
references.pmid: 22583931
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:203-26
references.pmid: 15822175
references.citation: Curr Drug Targets. 2012 Dec;13(14):1738-49
references.pmid: 23140285
references.citation: Int J Colorectal Dis. 2011 Jan;26(1):29-35
references.pmid: 21079973
references.citation: Neurochem Res. 2006 Oct;31(10):1247-54
references.pmid: 17006759
references.citation: Curr Colorectal Cancer Rep. 2013 Dec;9(4):350-357
references.pmid: 25584043
references.citation: Biomed Pharmacother. 2002 Aug;56(6):276-82
references.pmid: 12224598
references.citation: Biochim Biophys Acta. 2011 Jan;1813(1):238-59
references.pmid: 20969895
references.citation: Biochim Biophys Acta. 2004 Mar 1;1644(2-3):133-47
references.pmid: 14996498
references.citation: J Ethnopharmacol. 2014 Mar 14;152(2):227-42
references.pmid: 24463158
references.citation: Future Oncol. 2015;11(21):2911-22
references.pmid: 26414153
references.citation: World J Gastroenterol. 2014 Apr 21;20(15):4189-96
references.pmid: 24764657
references.citation: Pharmacogn Mag. 2013 Jan;9(33):51-7
references.pmid: 23661994
references.citation: Cancer Cell. 2012 Oct 16;22(4):419-20
references.pmid: 23079651
references.citation: Nutr Res. 2011 Feb;31(2):77-87
references.pmid: 21419311
references.citation: Front Pharmacol. 2013 Jun 26;4:80
references.pmid: 23805102
references.citation: Springerplus. 2014 Jan 14;3:27
references.pmid: 24683532
references.citation: Cell Death Dis. 2014 Mar 06;5:e1104
references.pmid: 24603332
references.citation: Anticancer Agents Med Chem. 2014;14 (10 ):1363-75
references.pmid: 25244914
references.citation: J Surg Res. 2009 Jan;151(1):163-70
references.pmid: 18061616
references.citation: J Hematol Oncol. 2012 Oct 11;5:63
references.pmid: 23057939
references.citation: Biochem Biophys Res Commun. 2012 Feb 3;418(1):180-5
references.pmid: 22252293
references.citation: Dig Dis Sci. 2014 Oct;59(10):2367-80
references.pmid: 25027205
references.citation: Biochem Pharmacol. 2006 May 14;71(10):1397-421
references.pmid: 16563357
references.citation: J Mol Med (Berl). 2013 Sep;91(9):1029-37
references.pmid: 23636511
references.citation: BMC Cancer. 2007 Jun 01;7:95
references.pmid: 17543095
references.citation: PLoS One. 2014 Apr 11;9(4):e94508
references.pmid: 24728073
references.citation: Int J Mol Sci. 2008 Mar;9(3):213-28
references.pmid: 19325744
references.citation: Int J Mol Sci. 2012;13(1):651-64
references.pmid: 22312277
references.citation: Crit Rev Oncol Hematol. 2013 Jun;86(3):251-77
references.pmid: 23287077
references.citation: J Nutr. 2000 Aug;130(8S Suppl):2073S-85S
references.pmid: 10917926
references.citation: Int J Oncol. 2014 Oct;45(4):1707-14
references.pmid: 25096806